1
Clinical Trials associated with Autologous CAR19 T lymphocytes(Institute of Hematology and Blood Transfusion)Safety and Efficacy of Anti-CD19 Chimeric Antigen Receptor-modified Autologous T Cells (CART19) in Patients with Relapsed/refractory CD19+ Acute Lymphoblastic Leukemia and Non-Hodgkin's Lymphoma. a Dose Escalation, Open-label, Phase I Study.
Phase I Dose Escalation Study of CART19 Cells for Adult Patients With Relapsed / Refractory Acute Lymphoblastic Leukemia and Non-Hodgkin's Lymphoma.
100 Clinical Results associated with Autologous CAR19 T lymphocytes(Institute of Hematology and Blood Transfusion)
100 Translational Medicine associated with Autologous CAR19 T lymphocytes(Institute of Hematology and Blood Transfusion)
100 Patents (Medical) associated with Autologous CAR19 T lymphocytes(Institute of Hematology and Blood Transfusion)
100 Deals associated with Autologous CAR19 T lymphocytes(Institute of Hematology and Blood Transfusion)